Nanalysis Scientific Corp. Announces Grant of Stock Options

Rhea-AI Summary

Nanalysis Scientific Corp. (NSCIF) has announced the grant of 335,000 stock options to its Directors and Officers, allowing them to purchase shares at $1.10 each for five years. The options will vest over three years, with one-third vesting annually. Additionally, 135,000 Restricted Stock Units (RSUs) were granted to Directors, also vesting over the same period. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) spectrometers and has expanded its market presence following the acquisition of K'Prime, enhancing its sales and service capabilities in North America.

Positive

• Granting of 335,000 stock options incentivizes Directors and Officers.
• Granting of 135,000 Restricted Stock Units (RSUs) enhances retention.
• Recent acquisition of K'Prime strengthens North American sales and service.

Negative

• None.

CALGARY, AB, March 14, 2023 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) ("Nanalysis" or the "Company") announces that the Company's Board of Directors has granted 335,000 stock options to Directors and Officers of the Company, pursuant to the Company's stock option plan. Each option is exercisable to purchase one common share in the capital of the Company at $1.10 per share for a period of five years from the date of issuance. The options vest as to one-third on each of the 12 month, 24 month, and 36 month anniversary date of grant.  In addition, the Company granted 135,000 Restricted Stock Units ("RSU"'s) to Directors of the Company, pursuant to the Company's RSU plan.  Each RSU is exercisable for one common share in the capital of the Company for a period ending at the end of the calendar year, three years after the date of grant.  The RSUs vest as to one-third on each of the 12 month, 24 month, and 36 month anniversary date of grant.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC under NSCIF, and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis began selling a 100MHz device in 2020. The Company's new device is the most powerful and most advanced compact NMR device ever brought to market.  Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the Company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems and services for security applications.  Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance ("NMR") company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-grant-of-stock-options-301771287.html

SOURCE Nanalysis Scientific Corp.

FAQ

What stock options did Nanalysis Scientific Corp. grant?

Nanalysis Scientific Corp. granted 335,000 stock options at $1.10 per share.

When do the stock options for Nanalysis Scientific Corp. vest?

The stock options vest one-third annually over three years.

What are the details of the Restricted Stock Units granted by Nanalysis?

Nanalysis granted 135,000 RSUs, which vest one-third annually and are exercisable for three years.

What is Nanalysis Scientific Corp.'s primary business?

Nanalysis develops portable Nuclear Magnetic Resonance (NMR) spectrometers for industrial and laboratory markets.

What recent acquisition has Nanalysis Scientific Corp. made?

Nanalysis acquired K'Prime, boosting its North American sales and service capabilities.